Most women report poor sexual health after a diagnosis of breast cancer
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
How to predict long-term survival to assess eligibility for phase I trials?
Studies investigate the discriminatory capacity of existing prognostic scales and the factors associated with survival to help select patients who may benefit from participation in early phase trials
Novel antigens for cancer immunotherapy – a way to enhance effectiveness?
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
Long-term data confirm a survival benefit with adjuvant anthracycline-taxane-based chemotherapy in early breast cancer
Updated analysis of the ABC trials favors anthracycline-based regimens in terms of IDFS and RFI, but no OS, when compared to taxane-based chemotherapy
Perioperative tislelizumab improves survival in resectable NSCLC – a new standard of care?
Encouraging EFS and OS results were presented at an ESMO Virtual Plenary for the use of the immune checkpoint inhibitor prior and after surgery
Actinium-225 shows clinical activity in metastatic castration-resistant prostate cancer
Survival benefits of the radioligand therapy needs to be confirmed in further studies
Immunotherapy combination improves PFS in metastatic castration-resistant prostate cancer
Cabozantinib plus atezolizumab may represent a novel option for patients progressing on first-line hormonal therapy
Study shows that immunotherapy initiation at the end of life has increased over time
In US, the trend was more frequently seen at very low-volume and nonacademic centers than at high-volume and academic centers
Neoadjuvant chemotherapy does not improve survival in pancreatic cancer
In the NORPACT-1 study, adjuvant FOLFORINOX shows no additional benefit compared to upfront surgery in patients with resectable pancreatic ductal adenocarcinoma
A study reveals new insights into resistance mechanisms to hormonal therapy in breast cancer
ESR1 variants show to be predictive of response to fulvestrant and novel mutations have been identified